89Zr-DFO-J591 for ImmunoPET of Prostate-Specific Membrane Antigen Expression In Vivo

Zr-89 (half-life, 78.41 h) is a positron-emitting radionuclide that displays excellent potential for use in the design and synthesis of radioimmunoconjugates for immunoPET. In the current study, we report the preparation of Zr-89-desferrioxamine B (DFO)-J591, a novel Zr-89-labeled monoclonal antibody (mAb) construct for targeted immunoPET and quantification of prostate-specific membrane antigen (PSMA) expression in vivo. Methods: The in vivo behavior of Zr-89-chloride, Zr-89-oxalate, and Zr-89-DFO was studied using PET. High-level computational studies using density functional theory calculations have been used to investigate the electronic structure of Zr-89-DFO and probe the nature of the complex in aqueous conditions. Zr-89-DFO-J591 was characterized both in vitro and in vivo. ImmunoPET in male athymic nu/nu mice bearing subcutaneous LNCaP (PSMA-positive) or PC-3 (PSMA-negative) tumors was conducted. The change in Zr-89-DFO-J591 tissue uptake in response to high-and low-specific-activity formulations in the 2 tumor models was measured using acute biodistribution studies and immunoPET. Results: The basic characterization of 3 important reagents-Zr-89-chloride, Zr-89-oxalate, and the complex Zr-89-DFO-demonstrated that the nature of the Zr-89 species dramatically affects the biodistribution and pharmacokinetics. Density functional theory calculations provide a rationale for the observed high in vivo stability of Zr-89-DFO-labeled mAbs and suggest that in aqueous conditions, Zr-89-DFO forms a thermodynamically stable, 8-coordinate complex by coordination of 2 water molecules. Zr-89-DFO-J591 was produced in high radiochemical yield (>77%) and purity (>99%), with a specific activity of 181.7 +/- 1.1 MBq/mg (4.91 +/- 0.03 mCi/mg). In vitro assays demonstrated that Zr-89-DFO-J591 had an initial immunoreactive fraction of 0.95 +/- 0.03 and remained active for up to 7 d. In vivo biodistribution experiments revealed high, target-specific uptake of Zr-89-DFO-J591 in LNCaP tumors after 24, 48, 96, and 144 h (34.4 +/- 3.2 percentage injected dose per gram [%ID/g], 38.0 +/- 6.2 %ID/g, 40.4 +/- 4.8 %ID/g, and 45.8 +/- 3.2 %ID/g, respectively). ImmunoPET studies also showed that Zr-89-DFO-J591 provides excellent image contrast, with tumor-to-muscle ratios greater than 20, for the delineation of LNCaP xenografts between 48 and 144 h after administration. Conclusion: These studies demonstrate that Zr-89-DFO-labeled mAbs show exceptional promise as radiotracers for immunoPET of human cancers. Zr-89-DFO-J591 displays high tumor-to-background tissue contrast in immunoPET and can be used to delineate and quantify PSMA-positive prostate tumors in vivo.